The data suggests Entyvio is most effective in biologic-naïve patients where other therapies were ineffective.
Takeda conducted two post-hoc analyses of gemini data in UC patients. In those analyses, symptomatic improvements were documented in two-week intervals. Researchers measured patient-reported outcomes scores and for Mayo Clinic subscores for rectal bleeding and stool frequency.
Researchers found the greatest reported improvements were in patients who were biologically naïve. Such patients saw improvements as early as the second week.
Ontario, Canada-based Robarts Research Institute’s Director of Robarts Clinical Trials Brian Feagan, MD, said in a release, “The resolution of patient-reported symptoms for both ulcerative colitis and Crohn’s disease examined in these analyses signifies important treatment goals for patients and key indicators for response to treatment for physicians. The results support Entyvio’s value as a therapy for ulcerative colitis and Crohn’s disease with a recognized safety profile and short-and long-term efficacy.”
More articles on gastroenterology:
GI leader to know: Dr. Josh Evans of Midwest Gastrointestinal Associates
What patients think about IBS-C — 8 survey insights
7 things to know about ACG’s next president, Dr. Irving Pike
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
